Context
A leading PE firm was evaluating the acquisition of two divisions from a global pharmaceutical company to form a new business focused on manufacturing medications. To inform the investment thesis, the deal team needed to understand the cost to stand up the new business. Following close, the carved-out organization now requires guidance to separate from its former parent, establish a standalone operating company, and launch its next chapter while complying with complex pharmaceutical regulations.